CN107583034A - Application of the growth and differentiation factor 11 in ischemia apoplexy disease medicament is prepared - Google Patents
Application of the growth and differentiation factor 11 in ischemia apoplexy disease medicament is prepared Download PDFInfo
- Publication number
- CN107583034A CN107583034A CN201710805392.2A CN201710805392A CN107583034A CN 107583034 A CN107583034 A CN 107583034A CN 201710805392 A CN201710805392 A CN 201710805392A CN 107583034 A CN107583034 A CN 107583034A
- Authority
- CN
- China
- Prior art keywords
- gdf11
- ischemia
- cerebral
- brain
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to application of the growth and differentiation factor 11 in ischemia apoplexy disease medicament is prepared.The present invention is in Focal Cerebral Ischemia Reperfusion model caused by intraluminal middle cerebral artery occlusion in rats occlusion, it have studied treatment and prevention effect of the growth and differentiation factor (GDF11) to cerebral ischemia, it was found that GDF11, which has, reduces cortical ischemia volume, improve the function of recovering animal sports ability, and then the mechanism of action that GDF11 treats and prevents to cerebral ischemia is found, and this process is realized by activating Smad2/3 signal paths.GDF11 can be designed as to targeted drug and carry out prophylactic treatment cerebral arterial thrombosis, there are potential huge applications to be worth the treatment of cerebral arterial thrombosis clinical prevention, and the biological function for further research GDF11 is laid a good foundation.
Description
Technical field
The present invention relates to growth and differentiation factor 11 (Growth differentiation factor 11, GDF11) to make
Application in standby ischemia apoplexy disease medicament, belongs to ischemia apoplexy technical field of pharmaceuticals.
Background technology
Headstroke is one of clinical common disease, has the characteristics of incidence of disease, fatal rate and disability rate are high, headstroke
The origin cause of formation has two kinds, and one kind is due to that rupture of blood vessel in brain causes hemorrhagic cerebral apoplexy caused by bleeding, accounts for 20%;Another kind is due to
Thrombus obstruction cerebral artery cause intracerebral hypoxic-ischemic caused by ischemia apoplexy, account for 80%.After focal cerebral ischemia, ischemic core
Heart Regional Blood Flow drastically declines, neuron mortality, is irreversible after the necrosis in this region.But
Ischemic core domain edge, referred to as ischemic penumbra, it is considered to be the potential region saved.Treatment ischemia apoplexy at present
Conventional medicine has three major types, be respectively by promoting the thromboembolism treatment medicine of revascularization resurgent, by reducing cellular damage,
Improve the neuroprotective agent of brain blood flow, and Chinese herbal medicine treatment.But due to many medicines, there is curative effect is weak, side effect
The problems such as more, the medicine for finding highly effective and safe are still shouldered heavy responsibilities.
In recent years by parabiosis model find young mice blood and old blood mutually blended circulation when, can
So that function declines such as reducing muscular atrophy, heart failure, slow in reacting, cognitive ability all caused by aging
Relax and even return to previous level.Played a role by the GDF11 that numerous studies are the discovery that in blood, GDF11 is in blood
In expression be to be reduced with the increase at animal age, into aged mice body injection restructuring GDF11 albumen effect, with
It is directly injected into that the effect of young mice blood is the same into aged mice body, both can significantly improve the myocardial function of mouse,
Avoid heart failure;In addition, find when the GDF11 contents in aged mice body return to identical water in young mice body
Usually, the structure of the skeletal muscle relevant with aging and physical function damage are repaired, and strengthen the strength of aged mice and resistance to
Power;Research can strengthen the blood circulation of aged mice brain it has also been found that recombinating both GDF11 albumen and young mice blood, swash
The nerve stem cell proliferation of subependymal region living, promotes the existence of new neuron, and finally improve age-related brain work(
It can recover.
GDF11 be transforming growth factor β (Transforming growth factor beta, TGF-β) family into
Member, TGF-β family include many protein moleculars for planting and influenceing body functions and such as growing, make a variation and be immunized, wherein flesh generation suppression
Albumen myostatin and GDF11 homology are up to 90%, and actuating signal path is identical.GDF11 intracerebral expression more
Extensively, mainly in hypothalamus, hippocampus and Purkinje cell group, it by combining the receptors of activin II on cell membrane, and then
I receptor ALK4, ALK5 is recruited, activation downstream Smad2, Smad3 signal path plays a role.
The content of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of (Growth of growth and differentiation factor 11
Differentiation factor 11, GDF11) application in ischemia apoplexy disease medicament is prepared, available for preparing
ICVD medicine.
Technical solution of the present invention is as follows:
A kind of applications of growth and differentiation factor GDF11 in ischemia apoplexy disease medicament is prevented and treated.
According to currently preferred, the ischemia apoplexy disease is cerebral apoplexy.
It is injection according to currently preferred, described pharmaceutical dosage form.
Beneficial effect
1st, inventor is had found by studying, after cerebral ischemia re-pouring 24h, rat layer ischemic penumbra GDF11 expression
It is horizontal significantly to rise;After being overexpressed slow virus pretreated rats 12 days with GDF11, cerebral ischemia re-pouring model is established, discovery can
Rat cerebral ischemia volume is substantially reduced, reduces neurological deficit scoring.Its mechanism be by promote SVZ brain areas cell breed,
Strengthen the regeneration of peripheral vessels and suppress penumbra region Apoptosis mode, reduce damage caused by cerebral ischemia re-pouring;In brain
To intracerebroventricular injection vitro recombination GDF11 albumen after ischemia-reperfusion 24h, rat cerebral ischemia volume can be effectively reduced, reduces god
Scored through functional defect.Its mechanism is shielded by way of suppressing penumbra region Apoptosis;GDF11 is pre- in cerebral ischemia
Effect in anti-and treatment is realized by regulating and controlling Smad2/3 signal paths.This illustrates GDF11 and ischemia apoplexy is damaged
The preventive and therapeutic action of wound.
2nd, this application discloses GDF11 prevention and treatment ischemia apoplexy damage in effect and different effect machines
System, for ischemia apoplexy clinical prevention and treat and provide new targeted drug, it was demonstrated that GDF11 carries in ischemia apoplexy
Potential huge applications in preceding prevention and clinical treatment.
Brief description of the drawings
GDF11 immunohistochemical staining figures after 2 hours Figure 1A, rat ischemia Reperfu- sion 24h, wherein:45 μm of scale;
GDF11 positive cell dyeings count column diagram after 2 hours Figure 1B, rat ischemia Reperfu- sion 24h, wherein:The μ of scale 45
m;
When 2 hours Fig. 1 C, rat cerebral ischemia Reperfu- sion different time points, the horizontal changes of cortex penumbra region GDF11mRNA
Statistical chart;
Fig. 2A, MCAO rats with left intracerebroventricular external source recombinate GDF11 albumen, the brain section photo of TCC dyeing;In figure,
Arrangement represents the direction of brain from front to back, scale in order from left to right for section:10mm
Fig. 2 B, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, ischemic area volume statistical chart;
Before and after Fig. 3, MCAO rats with left intracerebroventricular external source restructuring GDF11 albumen, the statistical chart of Bederson scorings;
Fig. 4 A, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, ischemic cortex caspase-3 SABCs
Colored graph, wherein:45 μm of scale;
Fig. 4 B, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, ischemic cortex caspase-3 positive cells
The statistical chart of number;
Fig. 5 A, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, ischemic cortex TUNEL colored graphs, wherein:
45 μm of scale;;
Fig. 5 B, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, ischemic cortex TUNEL dyeing statistical charts;
Fig. 6 A, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, SVZ areas BrdU-nestin is immunized dual glimmering
Light tissue staining figure;
Fig. 6 B, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, SVZ areas Ki67 immunofluorescence tissue stainings
Figure;
Fig. 6 C, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, SVZ areas BrdU positive cell statistical charts;
Fig. 6 D, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, SVZ areas Ki67 positive cell statistical charts;
Fig. 7 A, MCAO rats with left intracerebroventriculars external source restructuring GDF11 albumen, CD31 immunohistochemistries around SVZ areas
Colored graph;
Fig. 7 B, MCAO rats with left intracerebroventriculars external source recombinate GDF11 albumen, and CD31 positive cells count around SVZ areas
Figure;
Fig. 8 A, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and MCAO models are established after 12 days, and TCC dyeing displays lack
Blood volume;In figure, arrangement represents the direction of brain from front to back, scale in order from left to right for section:10mm
Fig. 8 B, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and MCAO models, ischemic area volume system are established after 12 days
Meter figure;
Fig. 9, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and MCAO models, Bederson scoring systems are established after 12 days
Meter figure;
Figure 10 A, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and establish MCAO models, ischemic cortex after 12 days
Caspase-3 immunohistochemical staining figures, wherein:45 μm of scale;
Figure 10 B, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and establish MCAO models after 12 days, ischemic cortex
Caspase-3 positive cell statistical charts;
Figure 11 A, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and establish MCAO models, ischemic cortex TUNEL after 12 days
Colored graph, wherein:45 μm of scale;
Figure 11 B, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and establish MCAO models, ischemic cortex TUNEL after 12 days
Positive cell statistical chart;
Figure 12 A, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and establish MCAO models, SVZ areas BrdU- after 12 days
Double fluorescent tissue staining figure is immunized in nestin, wherein:45 μm of scale;
Figure 12 B, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and MCAO models are established after 12 days, and SVZ areas BrdU is positive
Cell counts figure;
Figure 13 A, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and establish MCAO models after 12 days, CD31 around SVZ areas
Immunohistochemical staining figure, wherein:45 μm of scale;
Figure 13 B, Rat Right intracerebroventricular injection GDF11 are overexpressed virus and establish MCAO models after 12 days, CD31 around SVZ areas
Positive cell statistical chart;
Figure 14 A, Western Blot give external source restructuring GDF11 albumen/pre- place of GDF11 overexpression viruses after showing ischemic
After reason, cortex penumbra region p-Smad2/3 expression result of variations;
Figure 14 B, Western Blot give external source restructuring GDF11 albumen, cortex penumbra region p-Smad2/3 after showing ischemic
The statistical chart of relative amount after internal reference standardizes;
After Figure 14 C, Western Blot show that GDF11 is overexpressed virus pretreatment, cortex penumbra region p-Smad2/3 warp
Cross the statistical chart of relative amount after internal reference standardizes.
Embodiment
Technical scheme is further elaborated with reference to Figure of description and embodiment, but the present invention is protected
Protect scope not limited to this.
The present invention, by the method for intracerebral cortex microinjection, have studied in Focal Ischemia-Reperfusion in Rats model
Treatment and prevention that GDF11 damages to ischemia apoplexy effects, simultaneously, it was found that GDF11 is treating and preventing ischemic
Different mechanism of action in headstroke damage.So as to facilitate the present invention.
Embodiment 1:Therapeutic action of the GDF11 foreign recombinant proteins in cerebral ischemia is given after ischemic
1. establish line brush Focal Ischemia-Reperfusion in Rats model (Middle cerebral artery
Occlusion, MCAO model):
Take 300 ± 5g of body weight Sprague-Dawley rats (purchased from Beijing company of dimension tonneau China), intraperitoneal injection 10%
Chloraldurate (0.3~0.4ml/100g body weight) after, lie on the back and be fixed on operating table, along neck median incision, blunt separation
Hypodermis, separation, which connects, pricks left common carotid (CCA), and separates internal carotid (ICA) and external carotid artery upwards along CCA
(ECA) crotch, ECA near-ends are ligatured.An osculum is cut in arteria carotis communis infall, a diameter of 0.25mm bolts line is inserted from osculum
Enter ICA about 20.5 ± 0.5mm, meet light resistance, show that bolt line through arteria cerebri media initiating terminal to near-end, will move in brain
Arteries and veins initiating terminal blocks, and connects and pricks internal carotid for line.Sew up the incision, put the end of a thread in external, bolt line is evacuated in neck during Reperfu- sion and moved
Arteries and veins initial part.Ischemia Time is 2h, and the Reperfu- sion time is 24h, every group of each 3~5 animal.Sham-operated control group is not inserted
Line, remaining operation are identical with experimental group.
2. detect cortex penumbra region GDF11 expression:
Ischemic 2 hours, after Reperfu- sion 24h, perfusion, take full brain to make frozen section, compared with rats in sham-operated group, pass through
The method of immunohistochemical staining finds notable compared with sham-operation group in cortex penumbra region, the quantity of GDF11 positive cells
Increase (sham-operation group:20.64±1.57;MCAO groups:29.78±2.03;Figure 1A and Figure 1B).In addition, take successfully the big of modeling
Mouse, ischemic 2 hours, take brain to be cut into slices after irrigating 2,6,12,24,48 hours respectively, TTC dyes are carried out in 37 DEG C of incubator
Color, cortical ischemia scope is judged according to coloration result, the tissue of adjacent brain piece cortex penumbra region is drawn materials, extracted total
RNA carries out fluorescence real-time quantitative PCR, and result of study finds that compared with sham-operation group (1 ± 0) GDF11 mRNA level in-site is small 2
When without significant change (0.93 ± 0.78), have within 6 hours, 12 hours significantly rise (1.69 ± 0.27;1.68 ± 0.21), and 24
Hour reaches highest (2.20 ± 0.22), and normal level (1.23 ± 0.33 is gradually restored to after 48 hours;Fig. 1 C)
3. intracerebral microinjection:
After the chloraldurate of SD rats (purchased from Beijing company of dimension tonneau China) intraperitoneal injection 10%, mouse brain is fixed on brain and stood
On body position indicator, calvarium portion skin is cut, exposure skull, using skull face lambda as body surface symbol, is taken out with micro sample adding appliance
PBS and 2ul (0.625ng/ μ l) GDF11 are taken according to literature method (J Cereb Blood Flow Metab, 1999,19 (12):
1329-1335) inject ventriculus sinister cerebri (coordinate:Front and rear (AP), -0.9mm;Left and right (L), ± 1.5mm;Carry on the back abdomen (V), -3.6mm),
MCAO models are made after 24 hours.
4.TCC dyeing shows infarcted region:
Experimental animal broken end is taken into brain after ischemia-reperfusion 24h, the thick coronal sections of 2mm is prepared from front to back, is placed in and contains
37 DEG C of constant-temperature incubation 30min, Nao Pianzhong cortical infarction areas are not in 2%TCC (triphenyltetrazolium chloride) normal saline solution
Dye and white is presented, undamaged brain tissue takes on a red color.4% paraformaldehyde is fixed 24h and taken pictures.Using digital medical graphical analysis
The area and infarct size of every brain piece of system measurement, and the volume and Infarction volume of every brain piece are calculated, PBS control group cortex
Ischemic volume ratio be 10.45 ± 1.99%, GDF11 pretreated group cortical ischemia volume ratios substantially reduce to 3.59 ±
1.75% (P<0.05 Fig. 2A, B).These results prompting GDF11 has protective effect to cerebral ischemia.
5. neurological deficit scores:
According to the 5 of Longa and Bederon points of methods of marking processed, scored after ischemic 2h Reperfu- sions 24h.Its mark that scores
Standard is:0 point, impassivity injury symptoms;1 point, it is impossible to full extension operation offside forelimb;2 points, turn-taked to offside;3 points, to right
Roll oblique;4 points, it is impossible to spontaneous walking, the loss of consciousness.0 point and 4 points of animal is given it up.Take the successful animal of modeling random
It is divided into two groups of MCAO1 and MCAO2, respectively before and after statistics injection external source restructuring GDF11 albumen, two groups of animals of MCAO1 and MCAO2
Neurological deficit scoring score value.As a result show, before given after ischemia, the god for the two groups of animals of MCAO1 and MCAO2 being randomly assigned
There is no difference (MCAO1 groups through functional defect scoring score value:1.88±0.35;MCAO2 groups:1.83 ± 0.21, Fig. 3).
Restructuring GDF11 albumen is given after cerebral ischemia so that rat functional defect scoring score value significantly reduces (MCAO1+PBS groups:
1.75±0.16;MCAO2+GDF11 groups:1.13±0.13;P<0.05, Fig. 3).As a result restructuring GDF11 eggs are given after prompting ischemic
Neurological deficit scoring, recovered part nervous function can be significantly reduced in vain.
6. cerebral cortex apoptotic cell detects:
After making ischemia-reperfusion injury model, after 2 hours Reperfu- sion 24h of ischemic, rat is subjected to cardiac perfusion, then breaked end
Brain is taken, is fixed overnight with 4%PFA, graded sucrose solutions sedimentation, series frost is carried out with frozen section embedding medium investing tissue and cuts
Piece, take frozen section to carry out fluorescent immunohistochemistry, as a result find compared with control group, injection restructuring GDF11 albumen
The positive cell number of the cortex penumbra region Neuron Apoptosis GAP-associated protein GAP (caspase-3) of cerebral ischemia-reperfusion significantly reduces in group
(control groups:52.41±5.33;GDF11 protein groups:29.14±3.82;Fig. 4 A, B).For further the result, hair
A person of good sense takes two groups of cerebral ischemia-reperfusion piece to carry out TUNEL dyeing, and experimental group and the visible different degrees of TUNEL of control group are positive thin
Born of the same parents are distributed, and have chromatin condensation, karyopycnosis, in the obvious Apoptosis feature (Fig. 5 A) such as brown color or yellowish-brown.With just
Normal control group is compared, and the cell quantity of apoptosis is remarkably decreased (control groups in the rat brain of injection restructuring GDF11 albumen:
12.62 ± 1.32%;GDF11 protein groups:5.44 ± 0.65%;Fig. 5 A, B).Result above illustrates to recombinate GDF11 albumen pair
The neuron of cerebral ischemia-reperfusion penumbra region has protective effect.
The horizontal detection of 7.SVZ brain areas propagation:
Rat line brush Focal Cerebral Ischemia Reperfusion model is established, 2 hours Reperfu- sions of ischemic are after 24 hours, according to
Longa and Bederon 5 points of methods of marking screening successful rats of modeling processed, are randomly divided into two groups, respectively to its ventriculus sinister cerebri
Vitro recombination GDF11 albumen and PBS are injected, cardiac perfusion takes brain after three days, BrdU (50mg/ is injected intraperitoneally within 2 hours before perfusion
Kg), immunohistochemical staining is carried out after frozen section, is as a result found compared with control group, ventriculus sinister cerebri injection restructuring GDF11 albumen
Rat significantly reduce (control groups in the SVZ brain area BrdU positive cell quantities of cerebral ischemia-reperfusion:138.64±6.56;GDF11
Protein groups:58.67±10.78;Fig. 6 A and C), the quantity of another cell proliferation markers Ki67 positive cells also significantly drops
It is low.Illustrate that recombinating GDF11 albumen inhibits horizontal (the control groups of the propagation of SVZ brain area nerve cells:223.36±16.01;
GDF11 protein groups:52.64±7.08;Fig. 6 B and D).The cerebral ischemia-reperfusion piece for injecting restructuring GDF11 albumen and PBS is taken to carry out respectively
Dyeing, immunohistochemistry double staining is carried out using cell proliferation markers BrdU and neural stem cell marker nestin,
As a result it is also BrdU positive cells to show nestin positive cells, prompts restructuring GDF11 albumen to inhibit SVZ brain area nerve cords thin
The propagation (Fig. 6 A) of born of the same parents.
8.SVZ brain area peripheral vesselses regeneration level detects:
Establish rat line brush focal cerebral ischemia in rats, after ischemic 2h Reperfu- sions 24h, the restructuring of intracerebroventricular injection external source
GDF11 albumen, cardiac perfusion is carried out after 3 days, then takes brain to cook frozen section, is exempted from by revascularization label CD31
Epidemic disease histochemical staining finds that in rat brain after the horizontal rises of GDF11, subependymal region peripheral vessels generative capacity is without significant changes
(control groups:30.58±3.04;GDF11 protein groups:30.85±2.50;Fig. 7 A, 7B).This explanation restructuring GDF11 albumen pair
Subependymal region peripheral vessels, which generates, has no influence, or the μ l of injection volume 2 of restructuring GDF11 albumen (0.625ng/ μ l) inadequate,
Obvious action can not be produced to the angiogenesis around subependymal region.
Embodiment 2:It is overexpressed GDF11 and pre-processes the prevention effect in cerebral ischemia
1.GDF11 is overexpressed virus efficacy detection:
In order to express GDF11 state in a kind of long-acting height of intracerebral structure, its prevention effect to cerebral ischemia is studied,
Inventor constructs GDF11 overexpression plasmids and is packaged into the slow virus with green fluorescent protein (GFP) first, and by internal
And the overexpression efficiency of experiment in vitro detection virus.293 cell recovery cultures are taken, after cell density reaches 80% or so respectively
The negative control virus and GDF11 for adding 5 μ g are overexpressed virus, do fluorescence real-time quantitative PCR after 48 hours, as a result show
GDF11 is overexpressed virus and improves 6 times of (control groups in mRNA level in-site than Empty virus group:1±0;GDF11 overexpression groups:
6.08±0.14).The alternative SD rats for taking health of inventor are divided into two groups (n=3), give intracerebroventricular injection negative control respectively
Each 2 μ l of virus are overexpressed with GDF11, treats that it expresses 14 days cardiac perfusions afterwards, takes brain to cook frozen section, it is considerable under the microscope
Observe obvious green fluorescence.Prove that GDF11 is overexpressed virus formulation success.
2. being overexpressed TCC dyeing after GDF11 pretreatments shows infarcted region:
Slow virus and each 2 μ l of negative control virus are overexpressed to lateral ventricle of rat brain injection GDF11, treats expressing viral 12 days
Afterwards, line brush Focal Cerebral Ischemia Reperfusion model is established, 2 hours Reperfu- sions of ischemic, by rat heart perfusion, take brain after 3 days
Frozen section is done, carries out TTC dyeing (Fig. 8 A).As a result show that rat and the injection of injection GDF11 overexpression slow virus are negative right
Compared according to the rat of virus, ischemic scope is remarkably decreased (control groups:11.34±2.22;GDF11 overexpression groups:3.44±
1.41;Fig. 8 A and B).Result above is consistent with the result of injection restructuring GDF11 albumen, prompts to be overexpressed GDF11 pretreatments to brain
Ischemic injuries have protective effect.
3. neurological deficit scores after being overexpressed GDF11 pretreatments:
Virus and each 2 μ l of negative control virus are overexpressed to lateral ventricle of rat brain injection GDF11, after expressing viral 12 days,
Line brush Focal Cerebral Ischemia Reperfusion model is established, after 3 days, the nervous function for recording rat lacks 2 hours Reperfu- sions of ischemic
Score value is fallen into, evaluation is overexpressed influence of the GDF11 pretreatments to rats with cerebral ischemia nervous function.As a result show that injection GDF11 crosses table
The rat functional defect scoring score value of da virus is significantly reduced (control groups:1.63±0.18;GDF11 is overexpressed
Group:1.13±0.13;Fig. 9).Prompting, which is overexpressed GDF11 pretreatments, there is protection to make nervous function caused by cerebral ischemia
With.
4. cerebral cortex apoptotic cell detects after being overexpressed GDF11 pretreatments:
The SD rats for choosing 250~300g carry out intracerebroventricular injection GDF11 overexpressions virus and each 2 μ of negative control virus
L, expressing viral establish line brush Focal Cerebral Ischemia Reperfusion model after 12 days, and 2 hours Reperfu- sions of ischemic carry out the heart after 3 days
Dirty perfusion, take brain to cook frozen section, then carry out immunohistochemical staining, as a result find compared with control group, intracerebroventricular injection
GDF11 is overexpressed the positive of the viral rat in the cortex penumbra region Neuron Apoptosis GAP-associated protein GAP (Caspase-3) of cerebral ischemia-reperfusion
Cell number significantly reduces (control groups:45.08±4.08;GDF11 overexpression groups:34.08±1.42;Figure 10 A and B).
After TUNEL coloration results show that GDF11 continuation is overexpressed, the TUNEL positive cell apoptosis quantity of cortex penumbra region is notable
Decline (control groups:55.23±1.81;GDF11 overexpression groups:38.29±2.07;Figure 11 A and B).Result above with note
It is consistent to penetrate GDF11 albumen results, further demonstrate GDF11 has protective effect to the neuron in cerebral ischemia-reperfusion.
5. it is overexpressed the horizontal detection of SVZ brain areas propagation after GDF11 pretreatments:
Naoliqing capsule injection GDF11 is carried out to rat and is overexpressed virus and each 2 μ l of negative control virus, expressing viral 12
Establish line brush cerebral ischemic model after it, 2 hours Reperfu- sions of ischemic 3 days, carry out after BrdU is injected intraperitoneally 2 hours, carrying out heart
Perfusion takes brain to cook frozen section, then does immunohistochemical staining, as a result finds that injection GDF11 is overexpressed the rat of virus in ischemic
The SVZ brain area BrdU positive cell numbers of brain significantly raise (control groups:101.75±6.40;GDF11 overexpression groups:
192.33±14.38;Figure 12 A and B).BrdU and neural stem cell marker nestin is subjected to immunohistochemical double-labeled dyeing, knot
Fruit confirms that GDF11 is overexpressed the propagation for remarkably promoting SVZ NSCs.
6. SVZ brain area peripheral vesselses regeneration level detects after being overexpressed GDF11 pretreatments:
Intracerebroventricular injection GDF11 is carried out to rat and is overexpressed virus and negative control virus after 12 days, establishes line brush office
Stove cerebral ischemic model, ischemic 2h Reperfu- sions 3 days, after carrying out cardiac perfusion, take brain to make frozen section, carry out SABC dye
Color, as a result find that GDF11 is overexpressed pretreatment and subependymal region vascular endothelial cell label CD31 expression can be caused significantly to increase
Add (control groups:40.34±5.91;GDF11 overexpression groups:151.1±26.31;Figure 13 A and B), this prompting GDF11 locates in advance
Reason has significant facilitation to the regeneration of MCAO rat SVZ brain areas peripheral vessels.
Embodiment 3:GDF11 is treated in cerebral ischemia and the molecular mechanism of prevention effect
The cortical ischemia Penumbra tissue of materials cerebral ischemia animal respectively, extraction albumen are Western Blot, as a result found
After having injected external source restructuring GDF11 albumen, intracerebral pSmad2/3 (control groups:1±0.09;GDF11 protein groups:2.0±
0.24;Figure 14 A and B) expression dramatically increase.GDF11 albumen is recombinated it can be seen from the result by regulating and controlling Smad2/3 ginsengs
With the therapeutic process of cerebral ischemia.
Cortical ischemia penumbra region histone is extracted, is detected through Western Blot, as a result finds that having injected GDF11 crosses table
After da virus, pSmad2/3 (control groups in rat brain:1±0.66;GDF11 overexpression groups:1.57±0.10;Figure 14 A and
C amount) dramatically increases.GDF11 is overexpressed the guarantor that cerebral ischemia is participated in by regulating and controlling Smad2/3 it can be seen from the result
Shield acts on.
Claims (3)
- A kind of 1. applications of growth and differentiation factor GDF11 in ischemia apoplexy disease medicament is prevented and treated.
- 2. application as claimed in claim 1, it is characterised in that the ischemia apoplexy disease is cerebral apoplexy.
- 3. application as claimed in claim 1, it is characterised in that described pharmaceutical dosage form is injection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710805392.2A CN107583034A (en) | 2017-09-08 | 2017-09-08 | Application of the growth and differentiation factor 11 in ischemia apoplexy disease medicament is prepared |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710805392.2A CN107583034A (en) | 2017-09-08 | 2017-09-08 | Application of the growth and differentiation factor 11 in ischemia apoplexy disease medicament is prepared |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107583034A true CN107583034A (en) | 2018-01-16 |
Family
ID=61051606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710805392.2A Pending CN107583034A (en) | 2017-09-08 | 2017-09-08 | Application of the growth and differentiation factor 11 in ischemia apoplexy disease medicament is prepared |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107583034A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110669143A (en) * | 2019-10-10 | 2020-01-10 | 中国人民解放军军事科学院军事医学研究院 | Short peptide and application thereof |
CN113397757A (en) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | Methods for testing the effect of laquinimod in the treatment of ischemic stroke |
CN113652449A (en) * | 2021-07-27 | 2021-11-16 | 浙江大学 | Targeting vector, kit, method and application for establishing premature brain failure mouse model based on Cre-Loxp conditional knockout gene |
EP4154001A4 (en) * | 2020-05-19 | 2024-06-05 | Elevian Inc | Methods and compositions for treating stroke |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107011430A (en) * | 2017-04-07 | 2017-08-04 | 哈尔滨医科大学 | A kind of growth and differentiation factor 11 of the truncation with biological activity and preparation method thereof |
-
2017
- 2017-09-08 CN CN201710805392.2A patent/CN107583034A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107011430A (en) * | 2017-04-07 | 2017-08-04 | 哈尔滨医科大学 | A kind of growth and differentiation factor 11 of the truncation with biological activity and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
ANJALI CHAUHAN等: "Abstract 65:restoration of growth differentiation factor 11 protects against stroke in Mice", 《INTERNATIONAL STROKE CONFERENCE ORAL ABSTRACTS》 * |
OISON KA等: "Association of growth differentiation factor 11/8, putative anti-ageing factor,with cardiovascular outcoms and overall mortality in humans: analysis of the heart and soul and hunts cohorts.", 《EUR HEART J.》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110669143A (en) * | 2019-10-10 | 2020-01-10 | 中国人民解放军军事科学院军事医学研究院 | Short peptide and application thereof |
CN110669143B (en) * | 2019-10-10 | 2021-05-14 | 中国人民解放军军事科学院军事医学研究院 | Short peptide and application thereof |
EP4154001A4 (en) * | 2020-05-19 | 2024-06-05 | Elevian Inc | Methods and compositions for treating stroke |
CN113397757A (en) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | Methods for testing the effect of laquinimod in the treatment of ischemic stroke |
CN113652449A (en) * | 2021-07-27 | 2021-11-16 | 浙江大学 | Targeting vector, kit, method and application for establishing premature brain failure mouse model based on Cre-Loxp conditional knockout gene |
CN113652449B (en) * | 2021-07-27 | 2023-10-03 | 浙江大学 | Targeting vector, kit, method and application for establishing brain premature senility mouse model based on Cre-Loxp conditional knockout gene |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107583034A (en) | Application of the growth and differentiation factor 11 in ischemia apoplexy disease medicament is prepared | |
CN1954825B (en) | Supermicro Tongxinluo Chinese herbal composite and its new usage | |
EP4309659A1 (en) | Complex for treating optic nerve disease, and preparation method therefor and use thereof | |
CN108686211A (en) | A kind of drug and therapy for treating liver fibrosis | |
CN109125731A (en) | Application of the Sema4D/PlexinB1 inhibitor in preparation treatment and prevention optical fundus blood vessel disease medicament | |
CN110724203A (en) | Short peptide for promoting TFEB (T-Epstein-Barr) nuclear translocation, linear short peptide based on short peptide and application of short peptide in relieving cerebral ischemic injury | |
CN109689083B (en) | Anti-angiogenic pharmaceutical composition containing cyclopentadepsipeptide as active ingredient | |
US11622964B2 (en) | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof | |
CN101548966A (en) | Application of salvianolic acid A in salvia miltiorrhiza | |
CN110339232A (en) | A kind of Chinese medicine composition prevented and/or treat ischemical reperfusion injury | |
KR20120056290A (en) | Pharmaceutical compositions for combating thrombotic diseases and their preparation and uses | |
CN102949708A (en) | Application of human sDR5 (soluble death receptor 5) protein or sDR5-Fc (fragment crystallizable) antibody fusion protein as pharmaceutical drugs for myocardial infarction | |
CN109937053A (en) | For treating the pharmaceutical composition containing mTOR inhibitors of macular degeneration | |
KR20180119790A (en) | Composition for preventing or treating erectile dysfunction comprising embryonic stem cells derived exosome | |
Kumar et al. | Toxicity and symptomatic identification of species involved in snakebites in the Indian subcontinent | |
KR101567954B1 (en) | Composition for preventing or treating erectile dysfunction comprising HGF protein or gene therefor and use thereof | |
CN109395015B (en) | Application of rheumatism and pain relieving traditional Chinese medicine composition in preparation of anti-angiogenesis medicine | |
CN109381456A (en) | Trifluoro icariine inhibits the application in autophagy drug in preparation activation Akt signal | |
KR101733160B1 (en) | Composition for preventing or treating erectile dysfunction comprising DKK3 | |
CN104491496B (en) | Application of the Gastrodin/Rhizoma Gastrodiae powder in anti-hepatic fibrosis medicines are prepared | |
CN108606981A (en) | Pulmonary fibrosis is treated with MSCs orientation chemotactic characteristic deliveries EPO | |
CN114306306B (en) | Application of 2-bromopalmitic acid in preparation of medicine for treating diseases related to spermatogenic dysfunction | |
CN103705696A (en) | Method for preparing powder injection for treating diabetes by using aloes and Chinese yam | |
CN108939092B (en) | Application of muscle cell ETV2 gene expression promoter in preparation of medicine for treating limb ischemic diseases | |
CN105853453A (en) | Application of baicalin in preparation of medicine for protecting heart development of fetus with pregnancy associated with diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180116 |
|
WD01 | Invention patent application deemed withdrawn after publication |